Allogene Therapeutics Stock News

Allogene has potential to have the first pivotal phase 2 study using its allogeneic CAR-T known as ALLO-501A for the treatment of patients with non-Hodgkin's Lymphoma. Trial results are to be released

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

Allogene's (ALLO) second-quarter earnings beat estimates. ALLO is on track to initiate a pivotal phase II study on ALLO-501A in large B cell lymphoma in the coming weeks.

Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET Company Participants Christine Cassiano – Chief Communications Officer David Chang – President

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 14.75% and 7.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA

Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric

Shares of Caribou Biosciences Inc. ( CRBU , Financial) are up more than 46% since last Thursday, leading the way for several beaten-down biotechs that also rose after investors got a look at the prese

Allogene's (ALLO) first-quarter earnings beat estimates. Upon removal of the FDA's clinical hold on its AlloCAR T candidates, ALLO continues to move forward with its pipeline.

Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q1 2022 Earnings Conference Call May 4, 2022 5:00 PM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President and Ch

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 5.08% and 39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC

The stock price of Allogene Therapeutics, a biotechnology company focused on T-cell therapies for solid tumors, has seen an 18% rise over the last month, white it's down 38% YTD. The stock price over

ALLO-316 was given Fast Track Designation for the treatment of patients with renal cell carcinoma.

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?